Table 2.
Primary and secondary outcomes in 1:1 PS-matched patients initiating hydroxychloroquine versus methotrexate
|
|
||||||
|---|---|---|---|---|---|---|
| Hydroxychloroquine (n = 27,231) | Methotrexate (n = 27,231) | Hydroxychloroquine vs Methotrexate | ||||
|
|
||||||
| N of events | IR/1,000 PY | N of events | IR/1,000 PY | RD/1,000 PY (95% CI) | HR (95% CI) | |
|
| ||||||
| Primary Outcomes | ||||||
|
| ||||||
| Sudden Cardiac Arrest or Ventricular Arrythmia | 102 | 3.67 | 109 | 3.57 | 0.11 (−0.87, 1.08) | 1.03 (0.79, 1.35) |
| MACE | 820 | 29.91 | 839 | 27.81 | 2.10 (−0.68, 4.88) | 1.07 (0.97, 1.18) |
|
| ||||||
| Secondary Outcomes | ||||||
|
| ||||||
| Cardiovascular Mortality | 389 | 13.99 | 366 | 11.96 | 2.03 (0.18, 3.89) | 1.17 (1.02, 1.35) |
| All-cause Mortality | 972 | 34.96 | 972 | 31.76 | 3.21 (0.24, 6.18) | 1.10 (1.01, 1.21) |
| Myocardial Infarction | 316 | 11.46 | 315 | 10.38 | 1.08 (−0.62, 2.79) | 1.10 (0.94, 1.28) |
| Stroke | 223 | 8.07 | 257 | 8.45 | −0.38 (−1.86, 1.10) | 0.95 (0.79, 1.14) |
| Hospitalized Heart Failure | 523 | 19.06 | 407 | 13.42 | 5.64 (3.55, 7.73) | 1.41 (1.24, 1.61) |
IR, incidence rate; PY, person-years; RD, rate difference; HR, hazard ratio; CI, confidence interval; MACE, 3-point major adverse cardiac events (i.e., myocardial infarction, stroke, and cardiovascular mortality).